The patient is an 11-year-old boy with a localized synovial sarcoma of the left jaw.
Pediatric Oncology
The patient was treated with multiagent chemotherapy consisting of 3 cycles of vincristine, actinomycin-D, and cyclophosphamide followed by 6 cycles of ifosfamide, vincristine, and doxorubicin. Although his clinical response to therapy was excellent, characterized by diminished jaw swelling and less pain, on imaging, the best response achieved was less than a partial response. He was treated with radiation therapy to the lesion, followed by resection and continued chemotherapy. The pathology after radiation and surgery demonstrated close, but clear, margins and poor necrosis.
During the course of treatment, the patient had several episodes of admission for fever and neutropenia. During radiation therapy, he required enteral feedings via a percutaneous gastrostomy. He developed moderate to severe neuropathy due to vincristine that resolved after therapy was completed. After surgery and radiation, he developed significant trismus that responded partly to acupuncture and massage.
Soft tissue sarcomas are cancers that develop in muscle or other soft tissues of the body. In children, the most common form of soft tissue sarcoma is rhabdomyosarcoma. The nonrhabdomyosarcomas are a group of soft tissue cancers that account for only 3% of childhood cancers; in this small group, synovial sarcomas are the most common. In adults, synovial sarcomas comprise close to 10% of sarcomas. 1 Thus, much of the information we have about this rare tumor is derived from the adult experience and literature. Synovial sarcomas may arise anywhere in the body. They are generally slow growing but may be very aggressive locally. Specific cytogenetic abnormalities have been associated with synovial sarcoma: more than 90% of the tumors have a t(X; 18) translocation. This translocation involves the gene SYT (at 18q11) and the SSX1 or SSX2 gene on the X chromosome (at Xp11). These genes are transcription regulators. There is some evidence to suggest that patients whose tumors demonstrate the SYT-SSX2 translocation have improved 5-year survival as compared with those patients with the SYT-SSX1 translocation. 2, 3 The natural history of synovial sarcoma includes a propensity for local recurrence as well as the development of pulmonary metastases. Good prognosis is inversely related to metastases at diagnosis, size >5 cm at diagnosis, inability to perform a complete excision, and the ability to surgically remove the tumor. 1, 4 Children generally have a better prognosis than adults. Head and neck synovial sarcomas have a poorer prognosis than those involving the extremities, with survival rates reported to be between 47% and 82%.
Appropriate treatment of synovial sarcoma requires surgical resection. When complete resection cannot be achieved without significant morbidity, radiation therapy is indicated for close or positive surgical margins. In a retrospective review of 219 patients with synovial sarcoma treated at 2 US centers and 1 Italian center between 1966 and 1999, the analysis included 45 patients with localized disease that could not be resected (group 3). Among these patients, the event-free survival at 5 years was 76% ± 8% if treated with radiation therapy and only 36% ± 13% if radiation was not given (P = .03). 1, 4 The role of chemotherapy in the control of this illness is more controversial. In the same retrospective review, 4 42 patients with localized disease received chemotherapy, and there was sufficient information about 30 of these patients to demonstrate a 60% complete or partial response to chemotherapy. However, there was insufficient information to show that chemotherapy significantly affected long-term prognosis among these patients.
In a phase II trial of vincristine, doxorubicin, and ifosfamide in children with nonrhabdomyosarcoma sarcomas, there were 16 patients with unresectable or metastatic synovial sarcoma. Nine of these 16 patients (56%) had a partial or complete response to chemotherapy. The progression-free survival for the synovial sarcoma patients was 56.3% at 3 years. Again, there was insufficient data to conclude that the responding patients had an improved long-term prognosis. 5 The inability to definitely show that prolonged survival is associated with chemotherapy among these patients is primarily due to the small numbers of patients and the lack of randomized trials. Given the documented response rates to chemotherapy among synovial sarcoma patients, regimens that include ifosfamide and/or cyclophosphamide and doxorubicin are generally recommended for young patients. A definitive answer to the role of chemotherapy in children with synovial sarcoma must await further prospective studies.
